NCT06970899 is a NA clinical trial of PATH EX CycloPE® Device in Sepsis, sponsored by PATH EX, Inc..

Who is sponsoring NCT06970899?

NCT06970899 is sponsored by PATH EX, Inc..

What drugs are being tested in NCT06970899?

Interventions in NCT06970899: PATH EX CycloPE® Device.

What condition does NCT06970899 study?

NCT06970899 studies Sepsis, Infection, Bacteremia Sepsis, Systemic Inflammatory Response Syndrome (SIRS).

Is NCT06970899 still recruiting?

NCT06970899 is currently active, enrolled. Last updated 14 May 2025.

Last reviewed 2025-05-14 · How we verify

NCT06970899

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Initial Feasibility Study of the CycloPE® Device

Active, enrolled NA Last updated 14 May 2025

What this trial tests

NA trial testing PATH EX CycloPE® Device in Sepsis in 15 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

11 June 2024

Primary endpoint
26 April 2025

15 May 2025

Quick facts

Lead sponsor	PATH EX, Inc.
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	11 June 2024
Primary completion	26 April 2025
Estimated completion	15 May 2025
Sites	1 location across Armenia

Drugs / interventions tested

PATH EX CycloPE® Device

Conditions studied

Sepsis — all drugs for Sepsis →
Infection — all drugs for Infection →
Bacteremia Sepsis — all drugs for Bacteremia Sepsis →
Systemic Inflammatory Response Syndrome (SIRS) — all drugs for Systemic Inflammatory Response Syndrome (SIRS) →

Sponsor

PATH EX, Inc.

Who can join

18 and older, any sex, with Sepsis or Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, prospective, single-arm clinical study to evaluate the feasibility, safety, and performance of the PATH EX CycloPE® device on suspected bacteremia-associated sepsis. All participants are adults diagnosed with suspected bacteremia-associated sepsis, admitted to the intensive care unit (ICU), and meet the inclusion criteria.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06970899 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PATH EX, Inc.
Last refreshed: 14 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06970899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing